Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Association of MRI findings with clinical characteristics and prognosis in patients with leptomeningeal carcinomatosis from non-small cell lung cancer.

Ko Y, Gwak HS, Park EY, Joo J, Lee YJ, Lee SH, Kwon JW, Shin SH, Yoo H.

J Neurooncol. 2019 Jul;143(3):553-562. doi: 10.1007/s11060-019-03190-3. Epub 2019 May 14.

PMID:
31089925
2.

Whole brain radiotherapy in management of non-small-cell lung carcinoma associated leptomeningeal carcinomatosis: evaluation of prognostic factors.

Ozdemir Y, Yildirim BA, Topkan E.

J Neurooncol. 2016 Sep;129(2):329-35. doi: 10.1007/s11060-016-2179-9. Epub 2016 Jun 15.

PMID:
27306442
3.

Cauda Equina Syndrome Secondary to Leptomeningeal Carcinomatosis of Gastroesophageal Junction Cancer.

Alkhotani A, Alrishi N, Alhalabi MS, Hamid T.

Case Rep Neurol. 2016 Apr 30;8(1):87-91. doi: 10.1159/000445869. eCollection 2016 Jan-Apr.

4.

Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer.

Gwak HS, Joo J, Kim S, Yoo H, Shin SH, Han JY, Kim HT, Lee JS, Lee SH.

J Thorac Oncol. 2013 May;8(5):599-605. doi: 10.1097/JTO.0b013e318287c943.

6.

Incidence and risk factors for leptomeningeal carcinomatosis in breast cancer patients with parenchymal brain metastases.

Jung JM, Kim S, Joo J, Shin KH, Gwak HS, Lee SH.

J Korean Neurosurg Soc. 2012 Sep;52(3):193-9. doi: 10.3340/jkns.2012.52.3.193. Epub 2012 Sep 30.

7.

Diagnostic and prognostic values of cerebrospinal fluid CYFRA 21-1 in patients with leptomeningeal carcinomatosis.

Hyun JW, Park JH, Kang BG, Park EY, Park B, Joo J, Kim JK, Kim SH, Jeong JH, Lee HW, Park KD, Choi KG, Hwang SH, Gwak HS, Kim HJ.

Oncotarget. 2017 Jun 8;8(32):53326-53335. doi: 10.18632/oncotarget.18405. eCollection 2017 Aug 8.

8.

Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis.

Kim HS, Park JB, Gwak HS, Kwon JW, Shin SH, Yoo H.

World J Surg Oncol. 2019 Mar 27;17(1):59. doi: 10.1186/s12957-019-1595-7.

9.

Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.

Lee SJ, Lee JI, Nam DH, Ahn YC, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ.

J Thorac Oncol. 2013 Feb;8(2):185-91. doi: 10.1097/JTO.0b013e3182773f21.

10.

Leptomeningeal carcinomatosis originating from advanced gastric cancer--a report of three cases and review of the literatures.

Kusumoto T, Kimura Y, Sugiyama M, Ohta M, Tsutsumi N, Sakaguchi Y, Ikejiri K, Oki E, Saeki H, Morita M, Ikeda T, Furuta T, Maehara Y.

Fukuoka Igaku Zasshi. 2013 Nov;104(11):456-63. Review.

PMID:
24620642
11.

Outcome after whole brain radiotherapy alone in intracranial leptomeningeal carcinomatosis from solid tumors.

Gani C, Müller AC, Eckert F, Schroeder C, Bender B, Pantazis G, Bamberg M, Berger B.

Strahlenther Onkol. 2012 Feb;188(2):148-53. doi: 10.1007/s00066-011-0025-8. Epub 2012 Jan 11.

PMID:
22231633
12.

Leptomeningeal carcinomatosis from gastric cancer: single institute retrospective analysis of 9 cases.

Kim NH, Kim JH, Chin HM, Jun KH.

Ann Surg Treat Res. 2014 Jan;86(1):16-21. doi: 10.4174/astr.2014.86.1.16. Epub 2014 Jan 1.

13.

Leptomeningeal carcinomatosis as primary manifestation of pancreatic cancer.

Trinh VT, Medina-Flores R, Chohan MO.

J Clin Neurosci. 2016 Aug;30:124-127. doi: 10.1016/j.jocn.2015.12.027. Epub 2016 Mar 10. Review.

PMID:
26972704
14.

Cerebrospinal fluid metabolomic profiles can discriminate patients with leptomeningeal carcinomatosis from patients at high risk for leptomeningeal metastasis.

Yoo BC, Lee JH, Kim KH, Lin W, Kim JH, Park JB, Park HJ, Shin SH, Yoo H, Kwon JW, Gwak HS.

Oncotarget. 2017 Sep 18;8(60):101203-101214. doi: 10.18632/oncotarget.20983. eCollection 2017 Nov 24.

15.

[Analysis of Clinicopathological Feature and Prognosis for 
Leptomeningeal Metastasis in Non-small Cell Lung Cancer].

Zhu M, Ren Y, Liu Y, Ban C, Gu H, Wang Z, Zhang Y.

Zhongguo Fei Ai Za Zhi. 2016 Aug 20;19(8):533-8. doi: 10.3779/j.issn.1009-3419.2016.08.09. Chinese.

16.

Gastric leptomeningeal carcinomatosis: multi-center retrospective analysis of 54 cases.

Oh SY, Lee SJ, Lee J, Lee S, Kim SH, Kwon HC, Lee GW, Kang JH, Hwang IG, Jang JS, Lim HY, Park YS, Kang WK, Kim HJ.

World J Gastroenterol. 2009 Oct 28;15(40):5086-90.

17.

Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations.

Gong L, Xiong M, Huang Z, Miao L, Fan Y.

Lung Cancer. 2015 Sep;89(3):268-73. doi: 10.1016/j.lungcan.2015.06.001. Epub 2015 Jun 24.

PMID:
26141219
18.

Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.

Lee E, Keam B, Kim DW, Kim TM, Lee SH, Chung DH, Heo DS.

J Thorac Oncol. 2013 Aug;8(8):1069-74. doi: 10.1097/JTO.0b013e318294c8e8.

19.

Leptomeningeal carcinomatosis as the initial manifestation of gastric adenocarcinoma: a case report.

Guo JW, Zhang XT, Chen XS, Zhang XC, Zheng GJ, Zhang BP, Cai YF.

World J Gastroenterol. 2014 Feb 28;20(8):2120-6. doi: 10.3748/wjg.v20.i8.2120.

20.

Leptomeningeal carcinomatosis after major remission to taxane-based front-line therapy in patients with advanced breast cancer.

Kosmas C, Malamos NA, Tsavaris NB, Stamataki M, Stefanou S, Gregoriou A, Rokana S, Vartholomeou M, Antonopoulos MJ.

J Neurooncol. 2002 Feb;56(3):265-73.

PMID:
12061734

Supplemental Content

Support Center